Curidium trademarks PsychINDx name for schizophrenia/bipolar disorder test:
This article was originally published in Clinica
London, UK-based personalised medicine company Curidium has filed worldwide trademark applications confirming PsychINDx as the name for its blood diagnostic test designed to classify patients with schizophrenia or bipolar disorder into four separate subgroups. The company claims that PsychINDx could improve treatment of these patients and aid the development of new drug treatments for these disorders. The global market for antipsychotics used in the treatment of these two illnesses was valued at $12.5bn in 2004 and is expected to grow to $20.5bn by 2009, according to Curidium.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.